Biotech News
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
ir.moonlaketx.com2026-05-06 15:27 EST
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody ® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic